{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T03:23:42Z","timestamp":1793849022861,"version":"4.6.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["CUP J33C22002920006"],"award-info":[{"award-number":["CUP J33C22002920006"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s00277-025-06425-8","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T03:32:08Z","timestamp":1749007928000},"page":"3319-3331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SARS-CoV-2 infection does not affect the outcome of patients with relapsed\/refractory large B-cell lymphoma treated with CAR T-cell therapy"],"prefix":"10.1007","volume":"104","author":[{"given":"Marianna","family":"Gentilini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Casadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cinzia","family":"Pellegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Argnani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Gugliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Carella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Stefoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Gabrielli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Desiderio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Mazzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluca","family":"Maglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco","family":"Bagnato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Broccoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bonifazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2112-2651","authenticated-orcid":false,"given":"Pier Luigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"issue":"1","key":"6425_CR1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s40164-023-00426-x","volume":"12","author":"T Zhang","year":"2023","unstructured":"Zhang T, Tian W, Wei S et al (2023) Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era. Exp Hematol Oncol 12(1):66. https:\/\/doi.org\/10.1186\/s40164-023-00426-x","journal-title":"Exp Hematol Oncol"},{"key":"6425_CR2","doi-asserted-by":"publisher","unstructured":"Ahmed N, Oluwole O, Mahmoudjafari Z, Suleman N, McGuirk JP (2024) Managing infection complications in the setting of chimeric antigen receptor T cell (CAR-T) therapy. Clin Hematol Int 6(2). https:\/\/doi.org\/10.46989\/001c.115932","DOI":"10.46989\/001c.115932"},{"issue":"1","key":"6425_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","volume":"20","author":"FL Locke","year":"2019","unstructured":"Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of Axicabtagene Ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial. Lancet Oncol 20(1):31\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(18)30864-7","journal-title":"Lancet Oncol"},{"issue":"10","key":"6425_CR4","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","volume":"22","author":"SJ Schuster","year":"2021","unstructured":"Schuster SJ, Tam CS, Borchmann P et al (2021) Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol 22(10):1403\u20131415. https:\/\/doi.org\/10.1016\/S1470-2045(21)00375-2","journal-title":"Lancet Oncol"},{"issue":"4","key":"6425_CR5","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl 25(4):625\u2013638. https:\/\/doi.org\/10.1016\/j.bbmt.2018.12.758","journal-title":"Biol Blood Marrow Transpl"},{"issue":"12","key":"6425_CR6","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1080\/10428194.2023.2243355","volume":"64","author":"JS Al-Ramahi","year":"2023","unstructured":"Al-Ramahi JS, Shahzad M, Li K et al (2023) Lessons learned from COVID-19 pandemic: outcomes after SARS-CoV-2 infection in hematopoietic cell transplant and cell therapy recipients. Leuk Lymphoma 64(12):1981\u20131991. https:\/\/doi.org\/10.1080\/10428194.2023.2243355","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"6425_CR7","doi-asserted-by":"publisher","first-page":"3633","DOI":"10.1111\/febs.15375","volume":"287","author":"CL Atzrodt","year":"2020","unstructured":"Atzrodt CL, Maknojia I, McCarthy RDP et al (2020) A guide to COVID-19: a global pandemic caused by the novel coronavirus SARS\u2010CoV\u20102. FEBS J 287(17):3633\u20133650. https:\/\/doi.org\/10.1111\/febs.15375","journal-title":"FEBS J"},{"issue":"1","key":"6425_CR8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.23750\/abm.v91i1.9397","volume":"91","author":"D Cucinotta","year":"2020","unstructured":"Cucinotta D, Vanelli M (2020) WHO declares COVID-19 a pandemic. Acta Bio Med Atenei Parm 91(1):157\u2013160. https:\/\/doi.org\/10.23750\/abm.v91i1.9397","journal-title":"Acta Bio Med Atenei Parm"},{"issue":"1","key":"6425_CR9","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/10408363.2021.1979462","volume":"59","author":"M Ciotti","year":"2022","unstructured":"Ciotti M, Ciccozzi M, Pieri M, Bernardini S (2022) The COVID-19 pandemic: viral variants and vaccine efficacy. Crit Rev Clin Lab Sci 59(1):66\u201375. https:\/\/doi.org\/10.1080\/10408363.2021.1979462","journal-title":"Crit Rev Clin Lab Sci"},{"issue":"23","key":"6425_CR10","doi-asserted-by":"publisher","first-page":"15443","DOI":"10.3390\/ijerph192315443","volume":"19","author":"F Beccia","year":"2022","unstructured":"Beccia F, Di Pilla A, Causio FA et al (2022) Narrative review of the COVID-19 pandemic\u2019s first two years in Italy. Int J Environ Res Public Health 19(23):15443. https:\/\/doi.org\/10.3390\/ijerph192315443","journal-title":"Int J Environ Res Public Health"},{"key":"6425_CR11","unstructured":"Scheda tecnica Cominarty (2022) Published Online Oct 6"},{"key":"6425_CR12","unstructured":"Scheda tecnica ChAdOx1-S (2021) Published Online January 29"},{"key":"6425_CR13","unstructured":"Piano strategico nazionale di vaccinazione COVID-19. Accessed June 30 (2024) https:\/\/www.epicentro.iss.it\/vaccini\/covid-19-piano-vaccinazione"},{"key":"6425_CR14","doi-asserted-by":"publisher","unstructured":"Stefanelli P, Trentini F, Petrone D et al (2022) Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022. Eurosurveillance 27(45). https:\/\/doi.org\/10.2807\/1560-7917.ES.2022.27.45.2200125","DOI":"10.2807\/1560-7917.ES.2022.27.45.2200125"},{"issue":"3","key":"6425_CR15","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.cmi.2022.10.030","volume":"29","author":"D Luque-Paz","year":"2023","unstructured":"Luque-Paz D, Sesques P, Wallet F, Bachy E, Ader F (2023) B-cell malignancies and COVID-19: a narrative review. Clin Microbiol Infect 29(3):332\u2013337. https:\/\/doi.org\/10.1016\/j.cmi.2022.10.030","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"6425_CR16","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1182\/bloodadvances.2021005616","volume":"6","author":"A Busca","year":"2022","unstructured":"Busca A, Salmanton-Garc\u00eda J, Corradini P et al (2022) COVID-19 and CAR T cells: a report on current challenges and future directions from the EPICOVIDEHA survey by EHA-IDWP. Blood Adv 6(7):2427\u20132433. https:\/\/doi.org\/10.1182\/bloodadvances.2021005616","journal-title":"Blood Adv"},{"issue":"12","key":"6425_CR17","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1038\/s41375-021-01466-0","volume":"35","author":"AM Spanjaart","year":"2021","unstructured":"Spanjaart AM, Ljungman P, De La Camara R et al (2021) Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European society for blood and marrow transplantation (EBMT) infectious diseases working party and the European hematology association (EHA) lymphoma group. Leukemia 35(12):3585\u20133588. https:\/\/doi.org\/10.1038\/s41375-021-01466-0","journal-title":"Leukemia"},{"key":"6425_CR18","unstructured":"B-Nhl R. Characteristics of novel coronavirus infections in patients with relapsed\/refractory B-cell non-Hodgkin's lymphoma treated with CAR-T cells and factors influencing them. 2023;44(10)."},{"issue":"4","key":"6425_CR19","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s12185-024-03711-5","volume":"119","author":"K Hayashino","year":"2024","unstructured":"Hayashino K, Seike K, Fujiwara K et al (2024) Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma. Int J Hematol 119(4):459\u2013464. https:\/\/doi.org\/10.1007\/s12185-024-03711-5","journal-title":"Int J Hematol"},{"issue":"5","key":"6425_CR20","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"issue":"3","key":"6425_CR21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2022","unstructured":"Hayden PJ, Roddie C, Bader P et al (2022) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for blood and marrow transplantation (EBMT) and the joint accreditation committee of ISCT and EBMT (JACIE) and the European haematology association (EHA). Ann Oncol 33(3):259\u2013275. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.003","journal-title":"Ann Oncol"},{"issue":"17","key":"6425_CR22","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1182\/blood-2018-11-887067","volume":"133","author":"AV Hirayama","year":"2019","unstructured":"Hirayama AV, Gauthier J, Hay KA et al (2019) The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood 133(17):1876\u20131887. https:\/\/doi.org\/10.1182\/blood-2018-11-887067","journal-title":"Blood"},{"issue":"4","key":"6425_CR23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1182\/blood.2021015209","volume":"140","author":"WA Bethge","year":"2022","unstructured":"Bethge WA, Martus P, Schmitt M et al (2022) GLA\/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany. Blood 140(4):349\u2013358. https:\/\/doi.org\/10.1182\/blood.2021015209","journal-title":"Blood"},{"issue":"1","key":"6425_CR24","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","volume":"14","author":"L Pagano","year":"2021","unstructured":"Pagano L, Salmanton-Garc\u00eda J, Marchesi F et al (2021) COVID-19 infection in adult patients with hematological malignancies: a European hematology association survey (EPICOVIDEHA). J Hematol OncolJ Hematol Oncol 14(1):168. https:\/\/doi.org\/10.1186\/s13045-021-01177-0","journal-title":"J Hematol OncolJ Hematol Oncol"},{"issue":"11","key":"6425_CR25","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/bloodadvances.2022009578","volume":"7","author":"JA Van Doesum","year":"2023","unstructured":"Van Doesum JA, Salmanton-Garc\u00eda J, Marchesi F et al (2023) Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post\u2013CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Adv 7(11):2645\u20132655. https:\/\/doi.org\/10.1182\/bloodadvances.2022009578","journal-title":"Blood Adv"},{"issue":"12","key":"6425_CR26","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1080\/10428194.2023.2248329","volume":"64","author":"KPL Cheok","year":"2023","unstructured":"Cheok KPL, Kirkwood AA, Creasey T et al (2023) Improved COVID-19 outcomes in CAR-T patients in the age of vaccination and preemptive pharmacotherapeutics. Leuk Lymphoma 64(12):2037\u20132041. https:\/\/doi.org\/10.1080\/10428194.2023.2248329","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"6425_CR27","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1080\/10428194.2022.2057487","volume":"63","author":"KPL Cheok","year":"2022","unstructured":"Cheok KPL, Kirkwood AA, Menne T et al (2022) Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis. Leuk Lymphoma 63(8):1980\u20131984. https:\/\/doi.org\/10.1080\/10428194.2022.2057487","journal-title":"Leuk Lymphoma"},{"issue":"26","key":"6425_CR28","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1182\/blood.2022017257","volume":"140","author":"L Pagano","year":"2022","unstructured":"Pagano L, Salmanton-Garc\u00eda J, Marchesi F et al (2022) Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey. Blood 140(26):2773\u20132787. https:\/\/doi.org\/10.1182\/blood.2022017257","journal-title":"Blood"},{"issue":"1","key":"6425_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13045-023-01423-7","volume":"16","author":"F Marchesi","year":"2023","unstructured":"Marchesi F, Salmanton-Garc\u00eda J, Buquicchio C et al (2023) Passive pre-exposure immunization by Tixagevimab\/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry. J Hematol OncolJ Hematol Oncol 16(1):32. https:\/\/doi.org\/10.1186\/s13045-023-01423-7","journal-title":"J Hematol OncolJ Hematol Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06425-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06425-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06425-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T08:01:03Z","timestamp":1753171263000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06425-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["6425"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06425-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. No AI was used.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Generative AI and AI-assisted technologies"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}